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Background
The structural conservation of the V3 region is related to
its biological function, and explains the ability of many
anti-V3 monoclonal Abs (mAbs) to cross-neutralize
diverse HIV-1 strains. Experiments were undertaken to
determine the proportion of Tier 1 and 2 viruses that are
neutralized by anti-V3 mAbs
Methods
Eighteen anti-V3 mAbs were developed from the cells of
individuals living in Cameroon, India and the New York
City area, respectively. The mAb neutralizing activity was
tested by titration in the TZM-bl cell assay against 34 Tier
1 and Tier 2 pseudoviruses (psVs) derived from the enve-
lopes of viruses from clades A, AG, B and C. IC50 values
of <50 μg mAb/ml were defined as positive for neutraliza-
tion.
Results
All 10 Tier 1 psVs from clades A, AG, B and C were neu-
tralized by one or more of the 18 mAbs. The median IC50
value for neutralization of Tier 1 psVs by anti-V3 mAbs
was 0.8 ug/ml. Of the 24 Tier 2 viruses from clades B and
C that constitute the current standard panels, 8 of 24 were
neutralized by one or more mAbs. The median IC50 value
for neutralizing anti-V3 mAbs against Tier 2 viruses was
34.5 μg/ml. The anti-V3 mAbs derived from Cameroonian
subjects (mostly infected with AG viruses) showed the
greatest breadth, neutralizing 3 clade C and 4 clade B Tier
2 viruses. Clade B-derived mAbs neutralized 1 clade C and
4 clade B psVs, and mAbs from Indian subjects neutral-
ized just two clade C Tier 2 viruses.
Conclusion
Neutralization of 100% of Tier 1 and 33% of Tier 2 viruses
in the standard panels by anti-V3 mAbs suggests that anti-
V3 Abs will be a useful and important component of a
protective vaccine-induced immune response.
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